DOI: 10.17343/sdutfd.1734949 ISSN: 1300-7416

Tasimelteon Attenuates Lung Injury Following Traumatic Brain Injury: Histopathological and Immunohistochemical Evidence in a Rat Model

Ali Serdar Oğuzoğlu, Musa Canan, Furkan Çağrı Oğuzlar, Halil Aşçı, Özlem Özmen
Show PDF Cite
ObjectiveTraumatic brain injury (TBI) frequently causes secondary damage in distant organs, particularly the lungs, contributing to poor clinical outcomes. We aimed to assess whether tasimelteon (TASI), a melatonin receptor agonist, could mitigate pulmonary injury resulting from TBI in a rat model.Material and MethodForty male Wistar albino rats were randomly allocated to four distinct experimental groups: control, trauma (TRA), TRA + TASI 1mg/kg, and TRA + TASI 10mg/ kg. TBI was induced via Marmarou’s weight-drop model. Lung tissue samples were evaluated 24 hours after TBI via histopathological and immunohistochemical analyses targeting B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and Tumor Necrosis Factor-alpha (TNF-α).ResultsTBI induced significant alveolar damage, hyperemia, edema, and elevated Bax and TNF-α expression while reducing anti-apoptotic Bcl-2 levels. TASI, particularly at 10 mg/kg, significantly reversed these histological and molecular alterations (p < 0.05).ConclusionTASI provides dose-dependent protection against TBI-induced lung injury through modulation of apoptotic and inflammatory pathways. Its melatoninergic actions may represent a promising therapeutic option for managing multi-organ complications post-TBI.

More from our Archive